Article
Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia.
American journal of hematology - 1 May 2015
Emadi Ashkan, Faramand Rawan, Carter-Cooper Brandon, Tolu Seda, Ford Laurie A, Lapidus Rena G, Wetzler Meir, Wang Eunice S, Etemadi Arash, Griffiths Elizabeth A
Abstract excerpt
Mutations in IDH1 and IDH2 occur in 15-20% of AML cases, resulting in the production of 2-hydroxyglutarate, which promotes aberrant hypermethylation of DNA in leukemic cells. Although these mutations have been shown to have prognostic implications for patients with AML, optimal treatment strategies have yet to be defined. We retrospectively identified forty-two patients with AML treated with DNA methyltransferase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.